Hardman, Clare S. http://orcid.org/0000-0002-1127-6446
Chen, Yi-Ling http://orcid.org/0000-0003-3758-0638
Wegrecki, Marcin http://orcid.org/0000-0002-3275-9850
Ng, Soo Weei http://orcid.org/0000-0002-9867-6353
Murren, Robert
Mangat, Davinderpreet
Silva, John-Paul
Munro, Rebecca
Chan, Win Yan http://orcid.org/0000-0001-6964-5091
O’Dowd, Victoria
Doyle, Carl
Mori, Prashant
Popplewell, Andy
Rossjohn, Jamie http://orcid.org/0000-0002-2020-7522
Lightwood, Daniel http://orcid.org/0000-0003-1433-7459
Ogg, Graham S. http://orcid.org/0000-0002-3097-045X
Funding for this research was provided by:
RCUK | Medical Research Council (MC_EX_MR/R022550/1, MC_UU_00008)
UCB | UCB UK
Article History
Received: 15 November 2021
Accepted: 17 November 2022
First Online: 7 December 2022
Competing interests
: C.S.H., Y.-L.C. and G.S.O. are on filed patents pertaining to the antibodies. R. Murren, D.M., J.P.S., R. Munro, W.Y.C., V.O.D., C.D., P.M., A.P. and D.L. are employees of UCB Pharma, which has initial licensing rights to the antibodies. The authors have no additional competing interests to declare.